The effects of a nurse-led HAPA-based discharge planning on post-operative outcomes in urolithiasis patients with double-J stents: protocol for a randomized controlled trial

护士主导的基于HAPA的出院计划对双J管置入术泌尿系结石患者术后结局的影响:一项随机对照试验方案

阅读:1

Abstract

INTRODUCTION: Patients with urolithiasis undergoing double-J stent placement often face challenges during the post-operative period, including insufficient discharge preparedness and difficulties in self-management. Discharge planning can assist patients during this critical period. However, the effects of delivering a nurse-led discharge planning program remain under-studied. This study aims to apply the Health Action Process Approach (HAPA) model to develop and evaluate a nurse-led discharge planning intervention. AIM: This randomized controlled trial evaluates the effectiveness of a nurse-led, HAPA-based discharge planning intervention in improving discharge preparedness, self-management behaviors, and quality of life in patients undergoing double-J stent placement for urolithiasis. METHODS: A total of 86 patients with urolithiasis undergoing double-J stent placement will be randomly assigned to either the intervention group (HAPA-based discharge planning + usual care planning) or the control group (usual care planning). The intervention consists of four phases: assessment, planning, implementation, and evaluation, delivered during hospitalization, with a 30-day follow-up post-discharge. Primary outcomes include discharge readiness, self-management ability, and quality of life, which will be assessed at baseline, discharge, and 7 and 30 days post-discharge. Secondary outcomes include complications following double-J stent placement and unplanned healthcare service utilization rate. DISCUSSION: The results of this study will provide empirical evidence supporting the application of the HAPA model in post-operative discharge planning for urolithiasis patients. If successful, this intervention could lead to significant improvements in self-management behaviors, reduce complications and unplanned healthcare service utilization rates, and ultimately enhance the quality of life for these patients. TRIAL REGISTRATION NUMBER: Registered in the Chinese Clinical Trial Registry (ChiCTR2400093503). VERSION IDENTIFIER: Version 1.0, 2024-11-07.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。